Preventing and treating osteoporosis: Strategies at the millennium

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 188-197

  Sherman, Sherry ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alendronate; Bisphosphonates; Bone; Estrogen replacement therapy; Fractures; Menopause; Osteoporosis; Prevention of osteoporosis; Risedronate; Risk factors; Selective estrogen receptor modulators; SERMs; Treatment of osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; GESTAGEN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D;

ADULT; AGED; AGING; ALZHEIMER DISEASE; BONE DENSITY; BONE STRENGTH; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; HEART PROTECTION; HIP FRACTURE; HUMAN; LIFESTYLE; MALE; MORBIDITY; MORTALITY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE; VITAMIN INTAKE; WEIGHT BEARING;

EID: 0035680423     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04020.x     Document Type: Conference Paper

References (25)

1. Interim report and recommendations of the World Health Organization Task Force for Osteoporosis
2. Who has osteoporosis? A conflict between clinical and public health perspectives
3. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
4. Osteoporosis prevention, diagnosis, and therapy
5. Treatment of postmenopausal osteoporosis
6. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
7. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
8. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
9. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
10. Vitamin D3 and calcium to prevent hip fractures in elderly women
11. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
12. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial
13. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss
14. Estrogen replacement therapy and fractures in older women
15. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
16. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
17. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
18. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
19. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
20. Raloxifene and estrogen: Comparative bone remodeling kinetics
21. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women
22. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
23. Randomised trial of alendronate on risk fo fracture in women with existing vertebral fractures
24. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial
25. The paradox of small changes in bone density and reductions in risk of fracture with raloxifene